Corporate ProfileOncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.
July 06, 2016
Oncobiologics, Inc. to Present at the 2016 Cantor Fitzgerald 2nd Annual Healthcare Conferencemore >
June 16, 2016
Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira® biosimilar)more >
June 10, 2016